celecoxib has been researched along with ATLL in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with Celecoxib was associated with activation of Bax, decreased expression of Mcl-1, loss of the mitochondrial membrane potential and caspase-9-dependent apoptosis." | 1.35 | Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. ( Brown, M; Nicot, C; Sinha-Datta, U; Taylor, JM, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sinha-Datta, U | 1 |
| Taylor, JM | 1 |
| Brown, M | 1 |
| Nicot, C | 1 |
1 other study available for celecoxib and ATLL
| Article | Year |
|---|---|
Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Celecoxib; Cell Line, Transformed; Cell Line, | 2008 |